Summary by Futu AI
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.